49755-46-6

Usage

Molecular Structure

A hydrochloride salt form of 1-pyrrolidinecarboximidamide

Type

Chemical compound

Applications

Pharmaceutical and industrial

Use as a synthetic intermediate

1-PCA monohydrochloride is used in the production of various pharmaceutical drugs.

Building block in organic synthesis

It serves as a fundamental component in creating more complex organic molecules.

Development of novel compounds

1-PCA monohydrochloride is utilized in the research and development of new compounds for potential medical use.

Antifungal properties

1-Pyrrolidinecarboximidamide, monohydrochloride exhibits antifungal characteristics, making it effective against fungal infections.

Potential treatment for fungal infections

1-PCA monohydrochloride has been studied for its possible applications in treating fungal infections.

Upstream product

• 123-75-1 pyrrolidine 
• 4023-00-1 1H-Pyrazole-1-carboxamidine 
• 867-44-7 S-Methylisothiourea sulfate 
• 1622148-58-6 4,6-dimethoxy-2-(pyrrolidine-1-yl)pyrimidine 
• 4023-02-3 1H-pyrazole-1-carboximidamide hydrochloride 

Downstream Products

• 13932-58-6 1-pyrrolidinecarboximidamide 
• 1002103-27-6 7-benzyl-2-pyrrolidin-1-yl-5,6,7,8-tetrahydro-3H-pyrido[3,4-d]-pyrimidin-4-one 

Relevant academic research and scientific papers

Synthesis, characterization and biological evaluation of novel 6-ferrocenyl-4-aryl-2-substituted pyrimidine derivatives

A new series of 6-ferrocenyl-4-aryl-2-substituted pyrimidines were synthesized and evaluated for in vitro antiamoebic activity against HM1:IMSS strain of Entamoeba histolytica. Out of 16 compounds 10 compounds have shown IC50 values in the range of 0.41-1.73 μM and 1.80 μM. Pyrimidine derivatives having thiomethyl group,chloro group and mono-,di-,and trimethoxy substitution,exhibited higher antiamoebic activity than the reference drug metronidazole (IC50 1.80 μM). The toxicological studies of these compounds on human kidney epithelial cell line showed that all compounds were non-toxic. 4-(4-Chlorophenyl)-6-ferrocenyl-2-piperidin-1-yl-pyrimidine (4f) was found most active (IC50 0.41 μM) and least toxic among all the compounds.

Synthesis, characterization and biological evaluation of novel 2,4,6-trisubstituted bis-pyrimidine derivatives

A new series of 2,4,6-trisubstituted bis-pyrimidines were synthesized and evaluated for in vitro antiamoebic activity against HM1:IMSS strain of Entamoeba histolytica. Out of 16 compounds 8 compounds have shown IC50 values in the range of 0.10-

2-Aminoquinazolines by Chan-Evans-Lam Coupling of Guanidines with (2-Formylphenyl)boronic Acids

A new method is presented for the synthesis of 2-aminoquinazolines, which is based on a Chan-Evans-Lam coupling of (2-formylphenyl)boronic acids with guanidines. Relatively mild conditions involving the use of inexpensive CuI as a catalyst and methanol as a solvent permit the application of the method to a wide range of substrates. Nonsubstituted, N-monosubstituted, and N,N-disubstituted guanidines can be used as reactants to give the corresponding 2-aminoquinazolines in moderate yields from readily available (2-formylphenyl)boronic acids.

Using N-substituted-2-amino-4,6-dimethoxypyrimidines in the synthesis of aliphatic guanidines

Abstract The use of 2-chloro-4,6-dimethoxypyrimdine as a tool for the syntheses of substituted guanidines is presented. This method, that we had previously shown to be very useful for aromatic amines, introduces an atom economical, cost effective and environmentally safe method for the installation of the guanidine functionality in aliphatic primary and secondary amines.

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.

AMIDE COMPOUND

There is provided a FAAH inhibitor and a prophylactic or therapeutic agent for cerebrovascular disorders or sleep disorders comprising it. The prophylactic or therapeutic agent comprises a compound of the formula (I0): wherein Z is oxygen or sulfur; R1 is aryl which may be substituted, or a heterocyclic group which may be substituted; R1a is a hydrogen atom, a hydrocarbon group which may be substituted, hydroxyl, etc.; R2 is piperidin-1,4-diyl which may be substituted, or piperazin-1,4-diyl which may be substituted; R3 is a group formed by eliminating two hydrogen atoms from a 5-membered aromatic heterocyclic group having 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, which may be further substituted, -CO-, etc.; and R4 is a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted; or a salt thereof.